Sarra Mestiri

Ms. Sarra Mestiri


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
AKAbdul Khan
Abdul Khan
VIVarghese Inchakalody
Varghese Inchakalody
SMSarra Mestiri
Sarra Mestiri
ZYZeenath Safira K. M. Yoosuf
Zeenath Safira K. M. Yoosuf
Said DermimeSaid Dermime
Said Dermime
Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitations such as invasiveness, high cost and limited applicability in longitudinal monitoring, liquid biopsy has gathered immense attention in CRC. Liquid biopsy has several advantages over tissue biopsy including ease of sampling, effective monitoring, and longitudinal assessment of treatment dynamics. Furthermore, the importance of liquid biopsy is signified by approval of several liquid biopsy assays by regulatory bodies indicating the powerful approach of liquid biopsy for comprehensive CRC screening, diagnostic and prognostics. Several liquid biopsy biomarkers such as novel components of the microbiome, non-coding RNAs, extracellular vesicles and circulating tumor DNA are extensively being researched for their role in CRC management. Majority of these components have shown promising results on their clinical application in CRC including early detection, observe tumor heterogeneity for treatment and response, prediction of metastases and relapse and detection of minimal residual disease. Therefore, in this review, we aim to provide updated information on various novel liquid biopsy markers such as a) oral microbiota related bacterial network b) gut microbiome-associated serum metabolites c) PIWI-interacting RNAs (piRNAs), microRNA(miRNAs), Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and d) circulating tumor DNAs (ctDNA) and circulating tumor cells (CTC) for their role in disease diagnosis, prognosis, treatment monitoring and their applicability for personalized management of CRC.

25 January 2025 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
SMSarra Mestiri
Sarra Mestiri
ASAna Sami
Ana Sami
Naresh SahNaresh Sah
Naresh Sah
DEDina Moustafa Abo El-Ella
Dina Moustafa Abo El-Ella
SKSabiha Khatoon
Sabiha Khatoon
Shafiul HaqueShafiul Haque
Shafiul Haque